• Eyou Robot Technology

  Participated · Series B · Aug 2026

  Founded in 2018 and cultivated in Xishan, Jiangsu Eyou Robot Technology focuses on the research and production of integrated servo joint modules that combine motors, reducers, drivers, and encoders. Its integrated joints emphasize compact structure, control precision, and operational stability, and the company serves over 500 domestic and overseas enterprises including AGIBOT, TARS, iFLYTEK, FAW, TCL, Midea, Siemens, and Haier. The business spans Japan, South Korea, North America, and Southeast Asia, with overseas markets showing sustained growth. Orders in hand for joints have surpassed 1.5 million sets in 2026, a 15-fold increase over its total shipments for 2025. To meet demand, Eyou established what it calls the world's first fully automated production line for integrated joints in Shanghai Zhangjiang Robot Valley, producing a harmonic joint in 60 seconds with a 98% pass rate. The company has put 36,000 square meters of factory space into use at its Wuxi production base and acquired 34 mu of industrial land for a new smart manufacturing facility that will support a delivery capacity of 10 million units.

• OriginFlow

  Participated · Series A · May 2026

  OriginFlow develops a NeuroScale data-collection paradigm that uses surface electromyography (sEMG) captured by a proprietary EMG acquisition kit and encoded by its PULSE foundation model to reconstruct human intent, hand posture, force magnitude, and multimodal continuous information. Founded in 2025 and operating officially for about five months, the company positions itself as a "picks-and-shovels" provider for embodied AI rather than a robot-body maker. It has optimized hardware design and supply-chain integration to reduce the price of its full data-collection equipment set to roughly 1,000 yuan, lowering barriers for large-scale deployment. OriginFlow is pursuing dataset-building through strategic cooperation with partners such as 58 Group for home-service scenarios and leading manufacturers for industrial settings. Financially, it has raised over 500 million yuan across angel, strategic, and Pre-A1 rounds to scale deployment and model development. The company acknowledges technical and commercial challenges ahead, including validation of engineering generalization in complex real-world scenarios, robustness to electromagnetic interference and non-standard environments, and sustaining a long-term commercial moat beyond one-time hardware sales.

• Neurophth Therapeutics

  Led · Series B · Feb 2021

  Neurophth Therapeutics develops AAV-based gene therapies for ophthalmic diseases, including advanced investigational programs such as NR082 for ND4-LHON. Its AAV platform has been validated by data from an investigator-initiated retinal gene therapy study. NR082 has received orphan drug designation from both the U.S. FDA and the EMA. The company’s pipeline also includes programs for autosomal dominant optic atrophy, optic neuroprotection, vascular retinopathy and other preclinical candidates. Neurophth has subsidiaries in China (Wuhan, Shanghai and Suzhou) and the U.S. (San Diego, CA) and is led by founder, chairman and CEO Bin Li. The firm intends to use the new proceeds to accelerate clinical trials, enhance R&D capabilities and expand its pipeline. Neurophth Therapeutics develops gene therapies targeting ophthalmic diseases, with its lead investigational candidate NR082 (NFS-01, rAAV2-ND4) for ND4-mediated LHON. NR082 has orphan drug designation from the U.S. FDA and its IND for a Phase 1/2/3 trial was approved by China NMPA in March 2021, with the first patient dosed in June 2021. The company’s pipeline includes ND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic retinopathy) and five other preclinical candidates. Neurophth has initiated scale-up of in-house manufacturing using single-use technologies at its Suzhou facilities to support future commercial demand. The company intends to use newly raised capital to accelerate growth, advance its lead LHON program ex-China, enrich its R&D pipeline through business development, and continue expanding its international-standard gene therapy manufacturing platform. Neurophth is a fully integrated genetic medicines company focused on AAV-delivered gene therapies for ocular diseases. Its lead investigational candidate is NR082 (rAAV2-ND4) for ND4-mediated Leber hereditary optic neuropathy (LHON), which received U.S. FDA orphan designation in Q3 2020. The company expects to advance NR082 toward IND submission and to initiate clinical trials in the first half of 2021. Neurophth is developing a pipeline of 10 gene therapy product candidates addressing both rare and common ocular diseases, including ND1-mediated LHON, autosomal dominant optic atrophy, glaucoma, and diabetic macular edema. It is building a commercially scalable GMP manufacturing facility in Suzhou and scaling up in-house manufacturing using single-use technologies, and plans to establish translational research centers. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and the US, Neurophth closed a Series A in early 2020 to initiate facility construction and accelerate nonclinical studies.

• Microtech Medical

  Participated · Equity · Dec 2020

  MicroTech Medical Co., Ltd. announced it raised CNY 575 million in a funding round on December 8, 2020. The capital was provided by a group of new and returning investors. The round was co-led by Tencent Holdings Ltd., IDG Capital Partners Co., Ltd., and Taikang Qianzhen Fund. Other participants included CICC Jia Cheng Investment Management, Sanzheng Health, China Everbright Limited (SEHK:165), Zhongjin Pucheng Investment, and 3H Health Investment Management. Returning investors included Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Lilly Asia Ventures, CD Capital, Shanghai Guofang FOF Equity Investment Management Co., Ltd., and Zhejiang Juren Capital Management Co., Ltd. The articles do not disclose use of proceeds, valuation, or operating metrics.

No current team members are available.